Table 6.
Event Rates at 1 Year in the Propensity Score Matched-Cohort
| Cancer (n = 1,343) | Days to Events | No Cancer (n = 1,343) | Days to Events | HR (95% CI) | p Value | |
|---|---|---|---|---|---|---|
| Primary ischemic endpoint | ||||||
| DOCE | 154 (11.5) | 48 (2, 180) | 137 (10.2) | 28 (1, 169) | 1.18 (0.93–1.50) | 0.181 |
| Primary bleeding endpoint | ||||||
| Bleeding BARC (2 to 5) | 107 (8.0) | 22 (2, 152) | 80 (6.0) | 47 (8, 175) | 1.55 (1.14–2.11) | 0.005 |
| Secondary endpoints | ||||||
| All-cause death | 169 (12.6) | 98 (19, 225) | 91 (6.8) | 99 (10, 220) | 2.03 (1.55–2.65) | <0.001 |
| Cardiac death | 91 (6.8) | 42 (4, 180) | 61 (4.5) | 54 (6, 192) | 1.64 (1.17–2.31) | 0.004 |
| Definite cardiac death | 55 (4.1) | 6 (2, 82) | 41 (3.1) | 10 (3, 130) | 1.44 (0.94–2.21) | 0.090 |
| Unclear death | 36 (2.7) | 157 (55, 263) | 20 (1.5) | 188 (72, 282) | 2.06 (1.15–3.67) | 0.015 |
| Cardiovascular death | 99 (7.4) | 42 (4, 179) | 68 (5.1) | 66 (7, 218) | 1.64 (1.18–2.27) | 0.003 |
| Noncardiovascular death | 70 (5.2) | 182 (98, 275) | 23 (1.7) | 104 (57, 220) | 3.10 (1.89–5.06) | <0.001 |
| Myocardial infarction | 57 (4.2) | 2 (1, 107) | 72 (5.4) | 2 (1, 101) | 0.77 (0.54–1.10) | 0.152 |
| Spontaneous myocardial infarction | 28 (2.1) | 118 (55, 238) | 36 (2.7) | 101 (15, 212) | 0.76 (0.46–1.27) | 0.303 |
| TV myocardial infarction | 45 (3.4) | 1 (0, 79) | 59 (4.4) | 1 (1, 53) | 0.78 (0.53–1.15) | 0.201 |
| Any revascularization | 79 (5.9) | 140 (25, 256) | 100 (7.5) | 108 (15, 210) | 0.79 (0.58–1.08) | 0.140 |
| Target lesion revascularization | 45 (3.4) | 147 (36, 250) | 49 (3.7) | 73 (8, 208) | 0.96 (0.63–1.45) | 0.831 |
| Target vessel revascularization | 60 (4.5) | 146 (35, 253) | 72 (5.4) | 96 (13, 210) | 0.87 (0.61–1.23) | 0.421 |
| Stent thrombosis (definite/probable) | 84 (6.3) | 2 (1, 18) | 82 (6.1) | 1 (1, 15) | 1.04 (0.76–1.41) | 0.814 |
| Acute | 38 (2.8) | 1 (0, 1) | 42 (3.1) | 1 (0, 1) | 0.90 (0.58–1.40) | 0.655 |
| Subacute | 33 (2.5) | 5 (3, 15) | 25 (1.9) | 9 (4, 15) | 1.33 (0.79–2.26) | 0.287 |
| Late | 14 (1.0) | 146 (84, 256) | 16 (1.2) | 162 (63, 222) | 0.93 (0.45–1.93) | 0.853 |
| Stroke | 28 (2.1) | 17 (4, 154) | 18 (1.3) | 116 (9, 215) | 1.69 (0.91–3.13) | 0.097 |
| Bleeding BARC (2) | 40 (3.0) | 33 (6, 203) | 30 (2.2) | 123 (53, 238) | 1.62 (0.98–2.70) | 0.061 |
| Bleeding BARC (3) | 71 (5.3) | 22 (1, 150) | 54 (4.0) | 35 (4, 134) | 1.47 (1.01–2.13) | 0.042 |
| Bleeding BARC (4) | 3 (0.2) | 1 (0, 34) | 4 (0.3) | 20 (11, 27) | 0.75 (0.17–3.35) | 0.706 |
| Bleeding BARC (5) | 4 (0.3) | 29 (9, 178) | 2 (0.2) | 149 (109, 190) | 4.00 (0.45–35.79) | 0.215 |
Values are n (%) or median (1st quartile, 3rd quartile). HR and 95% CI are computed from Cox models.
BARC = bleeding academic research consortium; CI = confidence interval; DOCE = device oriented composite endpoint, HR = hazard ratio; TV = target vessel.